prIME Downloadable Slides | prIME Oncology

prIME Oncology invites you to view prIME Downloadable Slides in Multiple Myeloma that focus on new hematology data just released from the 2010 Annual Hematology Meeting in Orlando.

prIME Downloadable Slides in Multiple Myeloma from the 2010 Annual Hematology Meeting in Orlando.

		These slide decks cover newly released data in multiple myeloma focusing on the following data releases: Abstract #37: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplant (AHSCT) for multiple myeloma (MM): CALGB 100104. Abstract #622: A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens Abstract #307: A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib Abstract #619: Phase 3b UPFRONT study: Safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients Abstract #985: Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) Abstract #862: Carfilzomib, lenalidomide and desamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial
		View the downloadable slides

This activity is supported by grants from Onyx Pharmaceuticals and Millennium: The Takeda Oncology Company.